New targets in pain, non-neuronal cells, and the role of palmitoylethanolamide

Open Pain Journal

Volumn 5, Issue 1, 2012, Pages 12-23

  Hesselink, Jan M Keppel ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

New targets; Non neuronal cells; Pain; Palmitoylethanolamide

Indexed keywords

AMITRIPTYLINE; BORTEZOMIB; CELECOXIB; DULOXETINE; FATTY ACID AMIDASE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; G PROTEIN COUPLED RECEPTOR 55; GABAPENTIN; IBUPROFEN; OXYCODONE; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; PREGABALIN; THALIDOMIDE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; BINDING AFFINITY; CARPAL TUNNEL SYNDROME; CELL PROTECTION; CENTRAL NERVOUS SYSTEM; CHRONIC INFLAMMATION; CHRONIC PAIN; DIABETIC NEUROPATHIC PAIN; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DYSMENORRHEA; EVENING DOSAGE; GLIA; HUMAN; ISCHIALGIA; LOW BACK PAIN; MAST CELL; MORNING DOSAGE; MULTIPLE MYELOMA; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROPATHIC PAIN; NEUROPROTECTION; PAIN ASSESSMENT; PATHOGENESIS; PELVIS PAIN SYNDROME; PERIPHERAL NERVOUS SYSTEM; POLYNEUROPATHY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PUDENDAL NEURALGIA; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NERVE CONDUCTION; TREATMENT DURATION; VISCERAL PAIN; VISUAL ANALOG SCALE;

EID: 84859552776     PISSN: None     EISSN: 18763863     Source Type: Journal    
DOI: 10.2174/1876386301205010012     Document Type: Review

References (148)

1. Wen YR, Tan PH, Cheng JK, et al. Microglia: a promising target for treating neuropathic and postoperative pain, and morphine tolerance. J Formos Med Assoc 2011; 110: 487-94.
2. Nakagawa T, Kaneko S. Spinal astrocytes as therapeutic targets for pathological pain. J Pharmacol Sci 2010; 114: 347-53.
3. McMahon SB, Cafferty WB, Marchand F. Immune and glial cell factors as pain mediators and modulators. Exp Neurol 2005; 192(2): 444-62.
4. Ren K, Dubner R. Interactions between the immune and nervous systems in pain. Nat Med 2010; 16(11): 1267-76.
5. Chiang CY, Dostrovsky JO, Iwata K, et al. Role of glia in orofacial pain. Neuroscientist 2011; 17: 303-20.
6. Thacker MA, Clark AK, Marchand F, et al. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth Analg 2007; 105(3): 838-47.
7. Vorobeychik Y, Gordin V, Mao J, et al. Combination therapy for neuropathic pain: a review of current evidence. CNS Drugs 2011; 25: 1023-34.
8. Thaler A, Gupta A, Cohen SP. Cannabinoids for pain management. Adv Psychosom Med 2011; 30: 125-38.
9. Jaggi AS, Singh N. Therapeutic targets for the management of peripheral nerve injury-induced neuropathic pain. CNS Neurol Disord Drug Targets 2011; 10: 589-609.
10. Kopsky DJ, Keppel HJM. High doses of topical amitriptyline in neuropathic pain: two cases and literature review. Pain Pract 2011; 12(2): 148-53.
11. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharma-cological treatment of neuropathic pain. Pain 2010; 150: 573-81.
12. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007; 4: CD005454.
13. Walsh KB. Targeting GIRK Channels for the Development of New Therapeutic Agents. Front Pharmacol 2011; 2: 64.
14. Estacion M, Waxman SG, Dib-Hajj SD. Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability. Mol Pain 2010; 8: 6-35.
15. Momin A, Wood JN. Sensory neuron voltage-gated sodium channels as analgesic drug targets. Curr Opin Neurobiol 2008; 18: 383-8.
16. Jasmin L, Vit JP, Bhargava A, Ohara PT. Can satellite glial cells be therapeutic targets for pain control? Neuron Glia Biol 2010; 6: 63-71.
17. Park SW, Yi JH, Miranpuri G, Satriotomo I, et al. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 2007; 320: 1002-12.
18. Raso GM, Esposito E, Vitiello S, et al. Palmitoylethanolamide stimulation induces allopregnanolone synthesis in C6 Cells and primary astrocytes: involvement of peroxisome-proliferator activated receptor-. J Neuroendocrinol 2011; 23: 591-600.
19. Zuo Y, Perkins NM, Tracey DJ, et al. Inflammation and hyperalgesia induced by nerve injury in the rat: a key role of mast cells. Pain 2003; 105(3): 467-79.
20. Freemont AJ, Jeziorska M, Hoyland JA, et al. Mast cells in the pathogenesis of chronic back pain: a hypothesis. J Pathol 2002; 197(3): 281-5.
21. Rudick CN, Bryce PJ, Guichelaar LA, et al. Mast cell-derived histamine mediates cystitis pain. PLoS One 2008; 3(5): e2096.
22. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126(3): 693-702.
23. Hoogerwerf WA, Gondesen K, Xiao SY, et al. The role of mast cells in the pathogenesis of pain in chronic pancreatitis. BMC Gastroenterol 2005; 5(1): 8.
24. Anaf V, Chapron C, El Nakadi I, et al. Pain, mast cells, and nerves in peritoneal, ovarian, and deep infiltrating endometriosis. Fertil Steril 2006; 86(5): 1336-43.
25. Wood JD. Visceral pain: spinal afferents, enteric mast cells, enteric nervous system and stress. Curr Pharm Des 2011; 17(16): 1573-5.
26. Ba'albaki H, Rapoport A. Mast cells activate the renin angiotensin system and contribute to migraine: a hypothesis. Headache 2008; 48(10): 1499-505.
27. Levy D, Burstein R, Kainz V, et al. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 2007; 130(1-2): 166-76.
28. Levy D. Migraine pain, meningeal inflammation, and mast cells. Curr Pain Headache Rep 2009; 13(3): 237-40.
29. Levy D, Kainz V, Burstein R, et al. Mast cell degranulation distinctly activates trigemino-cervical and lumbosacral pain pathways and elicits widespread tactile pain hypersensitivity. Brain Behav Immun 2012; 26(2): 311-7.
30. Yuan H, Zhu X, Zhou S, et al. Role of mast cell activation in inducing microglial cells to release neurotrophin. J Neurosci Res 2010; 88(6): 1348-54.
31. Garrison CJ, Dougherty PM, Kajander KC, et al. Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res 1991; 22: 1-7.
32. Meller ST, Dykstra C, Grzybycki D, et al. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology 1994; 33(11): 1471-8.
33. Wagner R, Myers RR. Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves. Neuroscience 1996; 73: 625-9.
34. Saadé NE, Jabbur SJ. Nociceptive behavior in animal models for peripheral neuropathy: spinal and supraspinal mechanisms. Prog Neurobiol 2008; 86: 22-47.
35. Myers RR, Shubayev VI. The ology of neuropathy: an integrative review of the role of neuroinflammation and TNFaxonal transport in neuropathic pain. J Peripher Nerv Syst 2011; 16: 277-86.
36. Berger JV, Deumens R, Goursaud S, et al. Enhanced neuroinflammation and pain hypersensitivity after peripheral nerve injury in rats expressing mutated superoxide dismutase 1. J Neuroinflammation 2011; 8: 33.
37. Kim CF, Moalem-Taylor G. Interleukin-17 contributes to neuroinflammation and neuropathic pain following peripheral nerve injury in mice. J Pain 2011; 12: 370-83.
38. Vallejo R, Tilley DM, Vogel L, et al. The role of glia and the immune system in the development and maintenance of neuropathic pain. Pain Pract 2010; 10: 167-84.
39. Cady RJ, Glenn JR, Smith KM, et al. Calcitonin Gene-Related Peptide Promotes Cellular Changes in Trigeminal Neurons and Glia Implicated in Peripheral and Central Sensitization. Mol Pain 2011; 6: 94.
40. Kadetoff D, Lampa J, Westman M, et al. Evidence of central in-flammation in fibromyalgia Increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol 2012; 242 (1-2): 33-8.
41. Clark AK, Staniland AA, Malcangio M. Fractalkine/cx3cr1 signalling in chronic pain and inflammation. Curr Pharm Biotechnol 2011; 12 (10): 1707-14.
42. Bao L, Zhu Y, Elhassan AM, et al. Adjuvant-induced arthritis: IL-1beta, IL-6 and TNF-alpha are up-regulated in the spinal cord. Neuroreport 2001; 12: 3905-8.
43. Sun S, Chen WL, Wang PF, et al. Disruption of glial function enhances electroacupuncture analgesia in arthritic rats. Exp Neurol 2006; 198: 294-302.
44. Sabato AF. Idiopathic Breakthrough Pain: a new hypothesis. Clin Drug Investig 2010; 30(2): 27-9.
45. Ohara PT, Vit JP, Bhargava A, et al. Gliopathic pain: when satellite glial cells go bad. Neuroscientist 2009; 15: 450-63.
46. De Leo JA, Tawfik VL, Lacroix-Fralish ML. The tetrapartite synapse: path to CNS sensitization and chronic pain. Pain 2006; 122: 17-21.
47. Grace PM, Rolan PE, Hutchinson MR. Peripheral immune contributions to the maintenance of central glial activation underlying neuropathic pain. Brain Behav Immun 2011; 25: 1322-32.
48. Romero-Sandoval EA, Horvath RJ, DeLeo JA. Neuroimmune interactions and pain: focus on glial-modulating targets. Curr Opin Investig Drugs 2008; 9(7): 726-34.
49. Wieseler-Frank J, Maier SF, Watkins LR. Glial activation and pathological pain. Neurochem Int 2004; 45: 389-95.
50. Schmid HH. Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? Chem Phys Lipids 2000; 108(1-2): 71-87.
51. Buznikov GA, Nikitina LA, Bezuglov VV, et al. A putative 'prenervous' endocannabinoid system in early echinoderm development. Dev Neurosci 2010; 32(1): 1-18.
52. Petrosino S, Iuvone T, Di Marzo V. N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. Biochimie 2010; 92(6): 724-7.
53. Kuehl FA Jr, Jacob TA, Ganley OH, et al. The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occuring antiinflammatory agent. J Am Chem Soc 1957; 79(19): 5577-8.
54. D'Argenio G, Petrosino S, Gianfrani C, et al. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med 2007; 85(5): 523-30.
55. Sarchielli P, Pini LA, Coppola F, et al. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology 2007; 32(6): 1384-90.
56. Darmani NA, Izzo AA, Degenhardt B, et al. Involvement of the cannabimimetic compound, N-palmitoylethanolamine, in inflammatory and neuropathic conditions. A review of the available preclinical data and first human studies. Neuropharmacology 2005; 48(8): 1154-63.
57. Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, et al. The endo-cannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis 2009; 33(1): 57-71.
58. Franklin A, Parmentier-Batteur S, Walter L, et al. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 2003; 23(21): 7767-75.
59. Loría F, Petrosino S, Mestre L, et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci 2008; 28(4): 633-41.
60. Re G, Barbero R, Miolo A, et al. Palmitoylethanolamide, endocan-nabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J 2007; 173(1): 21-30.
61. Rice AS, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 2002; 66(2-3): 243-56.
62. Calignano A, La Rana G, Giuffrida A, et al. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394(6690): 277-81.
63. Benvenuti F, Lattanzi F, De Gori A, et al. Activity of some derivatives of palmitoylethanolamide on carragenine-induced edema in the rat paw. Boll Soc Ital Biol Sper 1968; 44(9): 809-13.
64. Jonsson KO, Vandevoorde SV, Lambert DM, et al. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol 2001; 133(8): 1263-75.
65. Calignano A, La Rana G, Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 2001; 419: 191-8.
66. Mazzari S, Canella R, Petrelli L, et al. N-(2-hydroxyethyl)hexa-decanamide is orally active in reducing edema formation and in-flammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 1996; 300: 227-36.
67. Xanthos DN, Gaderer S, Drdla R, et al. Central nervous system mast cells in peripheral inflammatory nociception. Mol Pain 2011; 7: 42.
68. Leon A, Buriani A, Dal Toso R, et al. Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci 1994; 91(9): 3739-43.
69. Nicol GD, Vasko MR. Unraveling the story of NGF-mediated sensitization of nociceptive sensory neurons: ON or OFF the Trks? Mol Interv 2007; 7(1): 26-41.
70. Michaloudi H, Batzios C, Chiotelli M, et al. Mast cells populations fluctuate along the spinal dura mater of the developing rat. Brain Res 2008; 1226: 8-17.
71. Biteker M. Current understanding of Kounis syndrome. Exp Rev Clin Immunol 2010; 6(5): 777-88.
72. Park CS, Bochner BS. Potential targeting of siglecs, mast cell in-hibitory receptors, in interstitial cystitis. Int Neurourol J 2011; 15(2): 61-3.
73. Rudick CN, Pavlov VI, Chen MC, et al. Gender specific pelvic pain severity in neurogenic cystitis. J Urol 2012; 187(2): 715-24.
74. Oliveira SM, Drewes CC, Silva CR, et al. Involvement of mast cells in a mouse model of postoperative pain. Eur J Pharmacol 2011; 672(1-3): 88-95.
75. Haidl G, Duan YG, Chen SJ, et al. The role of mast cells in male infertility. Exp Rev Clin Immunol. 2011; 7(5): 627-34.
76. Klein MM, Lee JW, Siegel SM, et al. Endoneurial pathology of the needlestick-nerve-injury model of Complex Regional Pain Syndrome, including rats with and without pain behaviors. Eur J Pain 2012; 16 (1): 28-37.
77. Hamilton MJ, Hornick JL, Akin C, et al. Mast cell activation syn-drome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol 2011; 128(1): 147-52.
78. Afrin LB. Burning mouth syndrome and mast cell activation disorder. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 111(4): 465-72.
79. Ständer S, Raap U, Weisshaar E, et al. Pathogenesis of pruritus. J Dtsch Dermatol Ges 2011; 9(6): 456-63.
80. Kim DY, Jeoung D, Ro JY. Signaling pathways in the activation of mast cells cocultured with astrocytes and colocalization of both cells in experimental allergic encephalomyelitis. J Immunol 2010; 185(1): 273-83.
81. Facci L, Dal Toso R, Romanello S, et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci 1995; 92(8): 3376-80.
82. Cerrato S, Brazis P, Miolo A, et al. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNF release from canine skin mast cells. Vet Immunol Immunopathol 2010; 133(1): 9-15.
83. Cantarella G, Scollo M, Lempereur L, et al. Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem Pharmacol 2011; 82(4): 380-8.
84. Costa B, Colombo A, Bettoni I, et al. The endogenous ligand Palmitoylethanolamide relieves neuropathic pain via mast cell and microglia modulation. Proceedings 21st Annual Symposium of the International Cannabinoid Research Society (ICRS), July 2011, Chicago (USA).
85. Costa B, Comelli F, Bettoni I, et al. Targeting mast cells in neuropathic pain with the endogenous modulator palmitoylethanolamide. J Peripheral Nerv Syst 2009; 14(Suppl1): 10.
86. De Filippis D, Luongo L, Cipriano M, et al. Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol Pain 2011; 7: 3.
87. Esposito E, Paterniti I, Mazzon E, et al. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav Immun 2011; 25(6): 1099-112.
88. Koch M, Kreutz S, Böttger C, et al. Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferatoractivated receptor-. Neurotox Res 2011; 19(2): 330-40.
89. Muccioli GG, Stella N. Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology 2008; 54(1): 16-22.
90. Redlich S, Ribes S, Schütze S, et al. Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 and Streptococcus pneumoniae R6 by microglial cells. J Neuroimmunol 2012 Jan 11. [Epub ahead of print]
91. Luongo L, Guida F, Gatta L, et al. Palmitoylethanolamide systemic treatment reduces spinal and supraspinal formalin-induced neuroinflammation and allodynia XIV Congress of the European Shock Society. 2011, September, Taormina, Italy.
92. Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the antiinflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005; 67: 15-9.
93. D'Agostino G, La Rana G, Russo R, et al. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther 2007; 322(3): 1137-43.
94. Sasso O, Russo R, Vitiello S, et al. Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain. Pain 2012; 153(1): 33-41.
95. Pistis M, Melis M. From surface to nuclear receptors: the endocannabinoid family extends its assets. Curr Med Chem 2010; 17(14): 1450-67.
96. Ho WS, Barrett DA, Randall MD. Entourage effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol 2008; 155 (6): 837-46.
97. García Mdel C, Adler-Graschinsky E, Celuch SM. Enhancement of the hypotensive effects of intrathecally injected endocannabinoids by the entourage compound palmitoylethanolamide. Eur J Pharmacol 2009; 610(1-3): 75-80.
98. Lambert DM, DiPaolo FG, Sonveaux P, et al. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochim Biophys Acta 1999; 1440(2-3): 266-74.
99. Farquhar-Smith WP, Rice AS. A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factorinduced hyperalgesia. Anesthesiology 2003; 99(6): 1391-401.
100. Di Marzo V. "Direct" and "indirect" endocannabinoids: endogenous biomodulators with protective roles. 1st Symposium on Aliamides in Veterinary Dermatology, March 2012, Verona, Italy.
101. O'Sullivan SE, Kendall DA. Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 2010; 8: 611-6.
102. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007; 152; 576-82.
103. Godlewski G, Offertáler L, Wagner JA, et al. Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat 2009; 89: 105-11.
104. Carroll CB, Zeissler ML, Hanemann CO, et al. (9)THC exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. Neuropathol Appl Neurobiol 2012 Jan 11. doi: 10.1111/j.1365-2990.2011.01248.x [Epub ahead of print].
105. Ravingerova T, Adameova A, Carnicka S, et al. The role of PPAR in myocardial response to ischemia in normal and diseased heart. Gen Physiol Biophys 2011; 30(4): 329-41.
106. Cao Y, Wang Q, Zhou Z, et al. Changes of Peroxisome Proliferator-Activated Receptoron Crushed Rat Sciatic Nerves and Differentiated Primary Schwann Cells. J Mol Neurosci 2011 Nov 18. [Epub ahead of print].
107. Aloe L, Leon A, Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 1993; 39: C145-7.
108. De Filippis D, D'Amico A, Iuvone T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J Neuroendocrinol 2008; 20(1): 20-5.
109. Lau AH, Chow SS. Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells. Eur J Pharmacol 2003; 464(2-3): 229-35.
110. Nakagawa T, Kaneko S. Spinal astrocytes as therapeutic targets for pathological pain. J Pharmacol Sci 2010; 114: 347-53.
111. LoVerme J, Russo R, La Rana G, et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 2006; 3: 1051-61.
112. Naccarato M, Pizzuti D, Petrosino S, et al. Possible Anandamide and Palmitoylethanolamide involvement in human stroke. Lipids Health Dis 2010; 9: 47.
113. Schomacher M, Müller HD, Sommer C, et al. Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. Brain Res 2008; 1240: 213-20.
114. Guasti L, Richardson D, Jhaveri M, et al. Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain. Mol Pain 2009; 5: 35.
115. Yu HL, Deng XQ, Li YJ, et al. N-palmitoylethanolamide, an endocannabinoid, exhibits antidepressant effects in the forced swim test and the tail suspension test in mice. Pharmacol Rep 2011; 63(3): 834-9.
116. Scuderi C, Esposito G, Blasio A, et al. Palmitoylethanolamide counteracts reactive astrogliosis induced by -amyloid peptide. J Cell Mol Med 2011; 15(12): 2664-74.
117. Masek K, Perlík F, Klíma J, et al. Prophylactic efficacy of N-2-hydroxyethyl palmitamide (impulsin) in acute respiratory tract infections. Eur J Clin Pharmacol 1974; 7: 415-9.
118. Kahlich R, Klíma J, Cihla F, et al. Studies on prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory infections. Serologically controlled field trials. J Hyg Epidemiol Microbiol Immunol 1979; 23: 11-24.
119. Plesník V, Havrlantová M, Jancová J, et al. Impulsin in the prevention of acute respiratory diseases in school children. Cesk Pediatr 1977; 6: 365-9.
120. Wiedermannová D, Wiedermann D, Lokaj J. Prophylactic administration of impulsin to clinically healthy children.--effect on the serum proteins and metabolic activity of granulocytes (author's transl). Cas Lek Cesk 1978; 117: 1030-4.
121. Wiedermannová D, Lokaj J, Wiedermann D. Prophylactic administration of impulsin to clinically healthy children. The effect on T and B lymphocytes in peripheral blood (author's transl). Cas Lek Cesk 1979; 118: 1249-51.
122. Keppel Hesselink, JM. Palmitoylethanolamide (Normast): clinical trial overview available at http://www.chronicpaincoalition.com/1/24/502/-normast-clinical-trial-ove rview-details
123. G. Guida, A. de Fabiani, F. Lanaia, A. et al. La palmitoiletanolamida (Normast) en el dolor neuropatico cronico por lumbociatalgia de tipo compresivo: estudio clinico multicentrico. Dolor 2010; 25: 35-42.
124. Calabrò RS, Gervasi G, Marino S, et al. Misdiagnosed Chronic Pelvic Pain: Pudendal Neuralgia Responding to a Novel Use of Palmitoylethanolamide. Pain Med 2010; 11(5): 781-4.
125. Schifilliti C, Cucinotta L, Fedele V, et al. Palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. XIV Congress of the European Shock Society. September, Taormina, Italy 2011.
126. Bacci C, Cassetta G, Emanuele B, et al. Randomized split-mouth study on postoperative effects of palmitoylethanolamide for impacted lower third molar surgery. ISRN Surg. 2011 2011917350.
127. Bortolotti F, Russo M, Bartolucci ML, et al. Palmitoylethanolamide versus NSAID in the treatment of TMJ's pain. J Orofac Pain [in press].
128. Russo G, Parabita M. Decrease of spasticity and pain after stroke due to treatment with PEA. 14th congress European Shock Soc, Taormina, Italy 2011.
129. Mancardi GL, Infante MT, Capello E, et al. Palmitoylethanolamide relieves neuropathic pain associated to multiple sclerosis. XL National Congress of the Italian Neurological Society. Padova, Italy 2009.
130. Phan NQ, Siepmann D, Gralow I, et al. Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. J Dtsch Dermatol Ges 2010; 8: 88-91.
131. Assini A, Laricchia D, Pizzo R, et al. The carpal tunnel syndrome in diabetes: clinical and electrophysiological improvement after treatment with palmitoylethanolamide. Eur J Neurol 2010; 17(S3): 295.
132. Assini A, Laricchia D, Pizzo R, et al. Tunnel carpale nel paziente diabetico. Migliloramento clinico ed elettrofisiologico dopo trattamento con palmitoiletanolamide. [Carpal tunnel syndrome in the diabetic patient. Clinical and electrophysiologic improvement after treatment with palmitoylethanolamide]. 34th National Congress AISD New frontiers in pain medicine. May, Riccione, Italy 2011.
133. Conigliaro R, Drago V, Foster PS, et al. Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. Minerva Med 2011; 102(2): 141-7.
134. Biasiotta A, Di Stefano G, Leone C, et al. Efficacy of palmitoylethanolamide in patients with painful neuropathy. A clinical and neurophysiological open study. Preliminary results. Eur J Pain 2010; 4(1): 77.
135. Truini A, Biasiotta A, Di Stefano G, et al. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapyinduced painful neuropathy. CNS Neurol Disord Drug Targets 2012 Jan 10.
136. Desio P. Combination of oxycodone and palmitoylethanolamide for low back pain treatment. Rivista Siared di Anestesia e Medicina Critica 2011; 1(2): 62-71.
137. Desio P. Associazione tra pregabalin e palmitoiletanolamide per il trattamento del dolore neuropatico. [Association of palmitoyletha-nolamide and pregabalin in the management of neuropathic pain]. Pathos 2010; 17(4): 9-14.
138. Di Paolo A, Gianfelice V, Silvestri C, et al. La palmitoiletanolamide nel trattamento del dolore attivato dal sistema gliale: nostra esperienza. [Palmitoylethanolamide in the management of gliaactivated pain. Our experience] 34th National Congress AISD New frontiers in pain medicine. May 2011, Riccione, Italy.
139. Palomba R, Adfiletta S, Candiello A, et al. Multimodal analgesia for chronic pain: rationale and future directions. Naples Pain Conference. Napoli, Italy 2010.
140. Adiletta S, Candiello A, Arminio D, et al. Pregabalin and Palmitoylethanolamide in diabetic neuropathic pain: an randomized clinical trial. 34th AISD (Italian Association for the Study of Pain) Congress, Riccione, Italy 2011.
141. Dominguez CM, Diaz Martin AA, Ferrer FG, et al. Palmitoiletanolamida (PEA) en lumbociatica en asociacion al tratamiento habitual. [Palmitoylethanolamide in lumbosciatic pain in association with standard therapy] 8th National Congress of the Sociedad Española del Dolor. May Madrid, Spain 2010.
142. Canteri L et al. Reduction of analgesics in patients suffering from lumbosciatic pain, treated with palmitoylethanolamide. Dolor 2010; 25: 227-34.
143. Palomba R, De Simone MG, GIovannini A, et al. Use of palmitotlethanolamide (PEA) + polydatin in the chronic pelvic pain. SIAARTI, October 2010, Parma, Italy.
144. Fulghesu A, Magnini R, Mazzella S, et al. Treatment of adolescent dysmenorrhea by a new inhibitor of mast cells-induced inflammation (palmitoylethanolamide + trans polydatin). 16th Congress of Pediatric and Adolescent Gynecology, May Montpellier, France 2010.
145. Indraccolo U, Barbieri F. Effect of palmitoylethanolamidepolydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations. Eur J Obstet Gynecol Reprod Biol 2010; 150(1): 76-9.
146. Cobellis L, Castaldi MA, Giordano V, et al. Effectiveness of the association micronized N-Palmitoylethanolamine (PEA) transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur J Obstet Gynecol Reprod Biol 2011; 158: 82-6.
147. Kopsky DJ, Keppel Hesselink JM Nerve regeneration in neuropathic pain. Pain Med 2010; 10: 1576.
148. Keppel Hesselink JM. Glia as a new target for neuropathic pain, clinical proof of concept for palmitoylethanolamide, a glia modulator. Anesth Pain Intensive Care 2011; 15: 143-5.